Cam wasn’t sleeping. Not really. After a motorcycle crash in late 2023 left him with a shattered pelvis, broken ribs, and a spine that needed fusing, sleep became a distant memory. The oxycodone his doctors prescribed—just 15 milligrams a day—did nothing against the 24/7 agony. He would scream. He’d cry until he couldn’t breathe.
He was 36, out of alcohol detox for six months, and in desperate need of relief.
That’s when the Instagram ad popped up. 7-hydroxymitragynine, or 7-OH. It’s a compound extracted from kratom, but it hits opioid receptors far harder than the leaf itself ever could. For Cam, a car parts manufacturer from upstate New York, it was a lifeline. The pain stopped. He could move. He could drive. He could do laundry without collapsing in a heap on the kitchen floor.
It cost him about $500 a month. But the price of a life without pain seemed small compared to the cost of staying in it.
Now, that lifeline is being cut. The Drug Enforcement Administration is moving to ban 7-OH by placing it in Schedule I—the same restrictive category as heroin. Along with two similar compounds, MGM-15 and MGM-19, these substances face a temporary ban starting as early as August 5. The DEA wants to study them for two years, potentially making the prohibition permanent.
Cam isn’t worried about addiction. He’s worried about withdrawal.
“They’re fucking a lot of people,” he says, referring to the agency. “It’s caused me so much anxiety.”
The Pharmacology of Panic
To understand why this ban is so controversial, you have to look at the chemistry. 7-hydroxymitraginaine (7-OH) is an opioid agonist. It activates the same receptors as morphine or fentanyl. The DEA argues that because of its high abuse potential and pharmacological profile, selling it as a “botanical supplement” is a public health risk.
The Food and Drug Administration doesn’t actually check dietary supplements for safety before they hit store shelves. So, consumers are buying unregulated powders, capsules, and gummies with little idea of what’s actually in the bottle.
This lack of regulation leads to dangerous spikes in dosage. Some users develop high tolerances quickly. One user told WIRED he was spending $175 every few days. Eventually, the sickness became so bad he stopped working. He couldn’t pay rent. He went broke chasing the high, then broke chasing the cure.
But for many, like Cam, it’s not about the high. It’s about function. They use 7-OH to self-medicate chronic pain that doctors have failed to manage. When the government says “no,” these users are left with two bad options: suffer, or find a street drug that’s much more dangerous.
Cam has struggled with alcohol, heroin, and prescription opioids before. 7-OH helped him stay off booze. But if the ban forces him back into pain and misery? He sees the slide back to street opioids happening. He sees others making the same mistake. The risk isn’t just dependency. The risk is overdose.
Kratom’s Dirty Little Secret
There’s a rift forming in the herbal remedy space, and it’s messy. The mainstream kratom lobby hates 7-OH. Why? Because kratom, a Southeast Asian plant, contains only trace amounts of the compound naturally. Extracting and concentrating 7-OH makes it far more potent—and far more dangerous, in their eyes.
The lobby has gained allies in high places. The Trump administration has sided against 7-OH sales. Health Secretary Robert F. Kennedy called the industry “sinister,” claiming products are “marketed for children” due to the rise of colorful gummies. Homeland Security Secretary Markwayne Mullin backs the crackdown too. Both men have strong ties to the broader kratom industry. It’s not hard to see the business motivation here: remove the concentrated extract, protect the leaf.
But here is the catch that keeps users up at night: kratom does contain 7-OH, just in tiny bits. The DEA’s ban targets the concentrated stuff. Natural kratom won’t be banned federally. However, the body doesn’t always care about the label.
When Cam or other long-term users stop taking 7-OH or MGM-15, they get sick. Withdrawal feels like flu, sweat, anxiety, and chills. It feels like any other opioid withdrawal.
Cam uses MGM-15 because it lasts longer. He admits it feels like shit to come off it. But he’d rather feel that shit than the pain that came before.
The Withdrawal Nightmare
You don’t have to take our word for it. Look at the support groups. Reddit’s r/quitting7oh has 11,000 subscribers. Discord servers are filled with people asking: How do I stop? What helps the insomnia? Does Tums help the jitters?
Archie, a pharmacy student, knows the drill. He started using 7-OH last March for a jaw abscess. Three weeks in, he skipped a dose.
“I was drenched in sweat,” he says. “I couldn’t think. I couldn’t sit.”
He kept taking it until finals were over. Only then did he check his brand on a third-party testing site. The grade? An F. The product was stronger than advertised and contained MGM-17, a synthetic opioid not listed on the label. Unregulated. Unlabeled. Potentially lethal.
Once school ended, Archie checked into detox. Doctors put him on buprenorphine, an opioid treatment that weans patients off cravings. It’s the standard protocol for opioid addiction. It works. But it’s also a reminder of what they’re trying to escape.
Dr. Petros Levounis, a psychiatrist at Rutgers New Jersey Medical School, sees this pattern monthly. More patients are walking into his emergency room seeking help for kratom and 7-OH withdrawal. Doctors are getting better at spotting it, especially with figures like Joe Rogan and Andrew Huberton talking about the plant’s effects on their podcasts.
Still, 7-OH remains a novel substance in medical circles. We haven’t fully wrapped our heads around the best way to treat it. We know the detox protocol—similar to heroin withdrawal. But the long-term data? It’s thin.
The Gap in the Safety Net
The DEA’s move assumes that banning the substance will solve the problem. That’s a classic policy error. Addiction isn’t solved by making things harder to find. It’s treated by providing care.
Right now, that care is fragmented. Cam is terrified. Archie recovered, but he was a pharmacy student with resources. What about the factory worker? The veteran? The single parent?
When the ban kicks in, these users won’t disappear. They will adapt. They will find whatever they can find. The spike in overdose deaths isn’t a theory. It’s a statistical certainty waiting to happen.
Cam hopes he can ride this out. He wants to stay off street opioids. But he looks at his broken ribs, still healing in spirit if not in bone, and wonders how long he can hold the line without 7-OH.
“It’s allowed me to be active,” he says. To live.
Without it, he’s just in pain again. And the system has no real plan for him. Just a schedule. Just a ban. Just the silence that comes when the medicine runs out.
